Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Cann Reiterated Acceleron Pharma (NDAQ:XLRN) as “Hold”

NewYork Acceleron Pharma NDAQ:XLRN

Acceleron Pharma (NDAQ:XLRN) Rating Restated

Cann kept their “Hold” rating on Acceleron Pharma (NDAQ:XLRN)’s stock in an analyst report revealed to investors on Friday morning.

According to data compiled by Thomson Reuters, Acceleron Pharma (NDAQ:XLRN)’s stock is covered by 9 equity analysts across the Street, with 0 analysts giving it a Sell rating, 8 a Buy rating, while 0 consider it a Hold. The 12-month consensus target price for the stock is $47.33, which reflects an upside potential of 38.80% over the current price.

XLRN Stock Chart

Institutional Ownership

Novo A S had the largest stake with ownership of 903,833 shares as of Q2 2015 for 2.91% of the fund’s portfolio. Sectoral Asset Management Inc is another bull as the investment manager who is owning 481,765 shares of Acceleron Pharma or 1.71% of their fund’s portfolio. Moreover, Perceptive Advisors Llc have 1.38% of their fund’s portfolio invested in the company for 589,890 shares. The Massachusetts-based fund Ra Capital Management Llc revealed it had purchased a stake worth about 1.19% of the investment manager’s stock portfolio in Acceleron Pharma. The Illinois-based fund Oak Ridge Investments Llc is also positive about the stock, possessing 318,565 shares or 1.15% of their fund’s portfolio.

Acceleron Pharma (NDAQ:XLRN) Profile

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Acceleron Pharma (NDAQ:XLRN) traded up 0.44% on 23 June, hitting $34.1. A total of 906,496 shares of the company’s stock traded hands. This is up from average of 383,534 shares. Acceleron Pharma has a 52 week low of $23.07 and a 52 week high of $41.69. The company has a market cap of $1.38B and a P/E ratio of 0.

Get the latest Acceleron Pharma (NDAQ:XLRN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Cann Reiterated Acceleron Pharma (NDAQ:XLRN) as “Hold” appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

Cann Reiterated Acceleron Pharma (NDAQ:XLRN) as “Hold”


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription